



**Nuvo Pharmaceuticals® Announces
Director Election Results of its
Annual & Special Meeting of Shareholders**

MISSISSAUGA, ON, May 12, 2020 - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF) a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that at its 2020 Virtual Annual & Special Meeting of Shareholders held on May 11, 2020, all nominees listed in the management proxy circular dated March 27, 2020 were elected as directors of the Company.

The detailed results of the votes by proxy are as follows:

Director Nominees	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST	
	FOR	WITHHELD	FOR	WITHHELD
Daniel Chicoine	2,792,654	294,223	90.47%	9.53%
David A. Copeland	2,959,918	126,959	95.89%	4.11%
Anthony E. Dobranowski	2,962,488	124,389	95.97%	4.03%
Robert Harris	2,880,912	205,965	93.33%	6.67%
John C. London	2,791,176	295,701	90.42%	9.58%

About Nuvo Pharmaceuticals Inc.

Nuvo (TSX: NRI; OTCQX: NRIFF) is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy and dermatology. The Company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Nuvo's head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the U.S. Food and Drug Administration, Health Canada and E.U. approved manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S, Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the FDA. For additional information, please visit www.nuvopharmaceuticals.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations
Email: ir@nuvopharm.com